Meeting
2021 ASCO Annual Meeting
Cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma.
Authors
Luciano J. Costa
University of Alabama at Birmingham, Birmingham, AL
Luciano J. Costa , Yi Lin , Thomas G. Martin , Saurabh Chhabra , Saad Zafar Usmani , Sundar Jagannath , Natalie Scott Callander , Jesus G. Berdeja , Yubin Kang , Ravi Vij , Hong Tian , Satish Valluri , Jennifer Marino , Carolyn Chang Jackson , Arnob Banerjee , Ankit Kansagra , Jordan Mark Schecter , Shaji Kumar , Parameswaran Hari
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT03548207
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8030)
DOI
10.1200/JCO.2021.39.15_suppl.8030
Abstract #
8030
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
First Author: Andrew J Yee
Poster
2023 ASCO Annual Meeting
Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment of LCAR-B38M CAR-T: At least 5-year follow-up in LEGEND-2.
First Author: Jian-Qing Mi
Poster
2022 ASCO Annual Meeting
Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI.
First Author: Saad Zafar Usmani
Poster
2021 ASCO Annual Meeting
Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.
First Author: Larry D. Anderson, Jr